PubMed ID:
15602651
Public Release Type:
Journal
Publication Year: 2005
Affiliation: Benaroya Research Institute at Virginia Mason, 1201 9th Ave, Seattle, WA 98101, USA. cjgreen@benaroyaresearch.org
DOI:
https://doi.org/10.1007/s00125-004-1608-z
Authors:
Atkinson M,
Babu S,
Cuthbertson D,
DPT-1 study group,
Eisenbarth G,
Greenbaum CJ,
Krischer J,
Orban T,
Schatz D,
Wasserfall C,
Yu L,
Zeidler A
Studies:
Diabetes Prevention Trial of Type 1 Diabetes
Immunological and genetic markers can be used to assess risk of developing type 1 diabetes prior to the onset of clinical symptoms. Autoantibody-positive relatives of patients with type 1 diabetes are at increased risk for disease, while the presence of HLA DQA1*0102/DQB1*0602 is thought to confer protection. Using the unique population identified by the Diabetes Prevention Trial--Type Diabetes (DPT-1), our aim was to determine if these individuals were protected from type 1 diabetes.